AP301: Phase IIa data

Top-line data from a double-blind, Austrian Phase IIa trial in mechanically-ventilated ARDS patients showed that orally inhaled AP301 led to earlier onset and "more pronounced activation" of pulmonary edema clearance vs. placebo. Additionally, a subgroup analysis showed that AP301 significantly improved pulmonary edema clearance vs. placebo in patients with elevated Sequential Organ Failure Assessment (SOFA) scores. AP301 also improved oxygenation index and Murray Lung Injury scores vs. placebo. ...